We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

231 hedge funds and large institutions have $2.06B invested in Vir Biotechnology in 2023 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 83 increasing their positions, 75 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more call options, than puts

Call options by funds: $11M | Put options by funds: $6.98M

35% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 26

11% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 75

3% more funds holding

Funds holding: 224 → 231 (+7)

1.58% more ownership

Funds ownership: 64.66% → 66.24% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

6% less capital invested

Capital invested by funds: $2.18B → $2.06B (-$120M)

Holders
231
Holders Change
+7
Holders Change %
+3.13%
% of All Funds
3.68%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
35
Increased
83
Reduced
75
Closed
26
Calls
$11M
Puts
$6.98M
Net Calls
+$4.06M
Net Calls Change
+$1.52M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$43M
2
APM
Avidity Partners Management
Texas
+$20.2M
3
SI
Sofinnova Investments
California
+$16.8M
4
B
Braidwell
Connecticut
+$15.4M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$10.3M

Top Sellers

1
SIAU
SB Investment Advisers (UK)
United Kingdom
-$49.6M
2
Pacer Advisors
Pacer Advisors
Pennsylvania
-$28.1M
3
Morgan Stanley
Morgan Stanley
New York
-$14.8M
4
Capital Fund Management (CFM)
Capital Fund Management (CFM)
France
-$5.76M
5
Goldman Sachs
Goldman Sachs
New York
-$5.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
151
Franklin Resources
California
$283K +$55.4K +2,165 +22%
Zurich Cantonal Bank
152
Zurich Cantonal Bank
Switzerland
$270K -$14.7K -574 -5%
RG
153
Rathbones Group
United Kingdom
$258K – – –
E
154
Ergoteles
New York
$257K +$282K +11,031 New
AIMCA
155
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$255K -$120K -4,679 -30%
Two Sigma Advisers
156
Two Sigma Advisers
New York
$254K +$279K +10,900 New
Public Employees Retirement Association of Colorado
157
Public Employees Retirement Association of Colorado
Colorado
$253K – – –
WCM
158
Wedge Capital Management
North Carolina
$243K +$31.3K +1,223 +13%
CIC
159
Cornercap Investment Counsel
Georgia
$241K – – –
MF
160
Magnetar Financial
Illinois
$232K +$255K +9,954 New
Mitsubishi UFJ Asset Management
161
Mitsubishi UFJ Asset Management
Japan
$232K +$16.6K +648 +7%
NVCHI
162
New Vernon Capital Holdings II
New Jersey
$226K +$1.69K +66 +0.7%
BC
163
BIT Capital
Germany
$225K +$247K +9,650 New
Axa
164
Axa
France
$219K -$1.84M -71,800 -88%
AMCA
165
Arthur M. Cohen & Associates
Illinois
$214K – – –
DFCM
166
Dark Forest Capital Management
Puerto Rico
$213K +$234K +9,157 New
QT
167
Quantamental Technologies
New York
$211K +$232K +9,063 New
Royal Bank of Canada
168
Royal Bank of Canada
Ontario, Canada
$208K -$134K -5,233 -37%
PAMS
169
Pictet Asset Management (Switzerland)
Switzerland
$201K – – –
SOW
170
State of Wyoming
Wyoming
$175K -$62.8K -2,455 -25%
CM
171
Caption Management
Oklahoma
$175K +$192K +7,500 New
SAM
172
Shell Asset Management
Netherlands
$172K -$665 -26 -0.4%
CIA
173
Capital Impact Advisors
Massachusetts
$168K -$153K -5,963 -45%
KBC Group
174
KBC Group
Belgium
$142K -$15.8K -617 -9%
BTI
175
Blue Trust Inc
Georgia
$141K +$126K +4,937 +745%
5 6
7
8 9

VIR Hedge Fund Activity: Q1 2023 in Review

231 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2023, worth a combined $2.06B — down 5.5% from $2.18B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new VIR positions and 26 closed out — a net gain of 9 holders — while 83 added to existing stakes and 75 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $43M. The largest seller was SB Investment Advisers (UK), cutting an estimated $49.6M.

  • 231 institutional investors held Vir Biotechnology (VIR) as of Q1 2023, up from 224 in Q4 2022.
  • Funds reported $2.06B of Vir Biotechnology stock for Q1 2023, down 5.5% quarter-over-quarter.
  • 35 funds opened new Vir Biotechnology positions in Q1 2023 and 26 closed out, a net change of +9 holders.
  • The largest Vir Biotechnology buyer in Q1 2023 was Point72 Asset Management, an estimated $43M added.
  • The largest Vir Biotechnology seller in Q1 2023 was SB Investment Advisers (UK), an estimated $49.6M sold.

Based on aggregated 13F filings for Q1 2023.